Interferon-gamma release assays for diagnosis of latent tuberculosis infection: Evidence in immune-mediated inflammatory disorders

Current Opinion in Rheumatology

Volumn 23, Issue 4, 2011, Pages 377-384

  Smith, Rachel ^a   Cattamanchi, Adithya ^b   Steingart, Karen R ^c   Denkinger, Claudia ^d   Dheda, Keertan ^e   Winthrop, Kevin L ^f   Pai, Madhukar ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g MCGILL UNIVERSITY   (Canada)

Author keywords

diagnostics; HIV; immune mediated inflammatory diseases; interferon gamma release assays; latent tuberculosis

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; ARTICLE; AUTOIMMUNE DISEASE; BACTERIUM CULTURE; BCG VACCINATION; CROHN DISEASE; CYTOKINE RELEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; ENTERITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE MEDIATED INFLAMMATORY DISORDER; IMMUNOSUPPRESSIVE TREATMENT; INFANCY; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MIXED INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUBLIC HEALTH SERVICE; RHEUMATOID ARTHRITIS; RISK FACTOR; SCREENING; THORAX RADIOGRAPHY; TUBERCULIN TEST; ULCERATIVE COLITIS;

HUMANS; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; RHEUMATIC DISEASES; TUBERCULIN TEST;

EID: 79958839671     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283474d62     Document Type: Article

References (53)

1. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sectionsofthis statement. Am J Respir Crit Care Med 2000; 161: S221-S247.
2. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006; 2:602-610. (Pubitemid 44650948)
3. Winthrop KL. The risk and prevention of tuberculosis: screening strategies to detect latent tuberculosis among rheumatoid arthritis patients who use biologic therapy. Int J Adv Rheumatol 2010; 8:43-52.
4. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010; 36:1185-1206.
5. Jasmer RM, Nahid P, Hopewell PC. Clinical practice. Latent tuberculosis infection. N Engl J Med 2002; 347:1860-1866. (Pubitemid 35417778)
6. Pouchot J, Grasland A, Collet C, et al. Reliability of tuberculin skin test measurement. Ann Intern Med 1997; 126:210-214. (Pubitemid 27061574)
7. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev Cochrane Database Syst Rev 2000: CD001363.
8. Akolo C, Adetifa I, Shepperd S, Volmink J, Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010: CD000171.
9. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis. Part I. Latent tuberculosis. Expert Rev Mol Diagn 2006; 6:413-422. (Pubitemid 44174345)
10. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146:340-354. (Pubitemid 351650594)
11. Pai M, Menzies D. Interferon-gamma release assays: what is their role in the diagnosis of active tuberculosis? Clin Infect Dis 2007; 44:74-77. (Pubitemid 44968988)
12. Sester M, Sotgiu G, Lange C, et al. Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J 2011; 37:100-111.
13. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149:177-184.
14. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and nontuberculous mycobacteria? Int J Tuberc Lung Dis 2006; 10:1192-1204. (Pubitemid 44713473)
15. Zwerling A, Behr M, Varma A, et al. The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS Med 2011; 8:e1001012.
16. Cattamanchi A, Smith R, Steingart KR, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 2011; 56:230-238.
17. Dheda K, van Zyl Smit R, Badri M, Pai M. T-cell interferon-gamma release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings. Curr Opin Pulm Med 2009; 15:188-200.
18. Zwerling A, van den Hof S, Scholten J, et al. Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review. Thorax 2011. [Epub ahead of print]
19. Lienhardt C, Fielding K, Hane AA, et al. Evaluation of the prognostic value of IFN-gamma release assay and tuberculin skin test in household contacts of infectious tuberculosis cases in Senegal. PLoS One 2010; 5:e10508.
20. Hill PC, Jackson-Sillah DJ, Fox A, et al. Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS One 2008; 3:e1379.
21. Del Corral H, Paris SC, Marin ND, et al. IFNgamma response to Mycobacterium tuberculosis, risk of infection and disease in household contacts of tuberculosis patients in Colombia. PLoS One 2009; 4:e8257.
22. Bakir M, Millington KA, Soysal A, et al. Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact. Ann Intern Med 2008; 149:777-787.
23. Mahomed H, Hawridge A, Verver S, et al. The Tuberculin Skin Test Versus QuantiFERON TB Gold® in predicting tuberculosis disease in an Adolescent Cohort Study in South Africa. PLoS One 2011; 6:e17984.
24. Pai M. Spectrum of latent tuberculosis-existing tests cannot resolve the underlying phenotypes. Nat Rev Microbiol 2010; 8:242-243.
25. Van Zyl-Smit RN, Zwerling A, Dheda K, Pai M. Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS One 2009; 4:e8517.
26. Bartalesi F, Vicidomini S, Goletti D, et al. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 2009; 33:586-593.
27. Behar SM, Shin DS, Maier A, et al. Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immuno-suppressive therapy. J Rheumatol 2009; 36:546-551.
28. Bocchino M, Matarese A, Bellofiore B, et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis 2008; 27:907-913.
29. Cobanoglu N, Ozcelik U, Kalyoncu U, et al. Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers. Int J Tuberc Lung Dis 2007; 11:1177-1182. (Pubitemid 350146297)
30. Gogus F, Gunendi Z, Karakus R, et al. Comparison of tuberculin skin test and QuantiFERON-TB gold in tube test in patients with chronic inflammatory diseases living in a tuberculosis endemic population. Clin Exp Med 2009; 10:173-177.
31. Kleinert S, Kurzai O, Elias J, et al. Comparison of two interferon-gamma release assays and tuberculin skin test for detecting latent tuberculosis in patients with immune-mediated inflammatory diseases. Ann Rheum Dis 2010; 69:782-784.
32. Kwakernaak AJ, Houtman PM, Weel JF, et al. A comparison of an interferon-gamma release assay and tuberculin skin test in refractory inflammatory disease patients screened for latent tuberculosis prior to the initiation of a first tumor necrosis factor alpha inhibitor. Clin Rheumatol 2011; 30:505-510.
33. Laffitte E, Janssens JP, Roux-Lombard P, et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test. Br J Dermatol 2009; 161:797-800.
34. Marques CD, Duarte AL, de Lorena VM, et al. Evaluation of an interferon gamma assay in the diagnosis of latent tuberculosis infection in patients with rheumatoid arthritis. Rheumatol Int 2009. [Epub ahead of print]
35. Martin J, Walsh C, Gibbs A, et al. Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis. Ann Rheum Dis 2009; 69:181-185.
36. Matulis G, Juni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 2008; 67:84-90.
37. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008; 35:776-781. (Pubitemid 351747116)
38. Schoepfer AM, Flogerzi B, Fallegger S, et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol 2008; 103:2799-2806.
39. Vassilopoulos D, Stamoulis N, Hadziyannis E, Archimandritis AJ. Usefulness of enzyme-linked immunosorbent assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for antitumor necrosis factor treatment. J Rheumatol 2008;35:1271-1276. (Pubitemid 352000770)
40. Diel R, Hauer B, Loddenkemper R, et al. Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases. Pneumologie 2009; 63:329-334.
41. Beglinger C, Dudler J, Mottet C, et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly 2007; 137:620-622.
42. Swiss Lung Association. Handbuch Tuberkulose 2011 (Handbook Tuberculosis 2011)-preliminary version. http://www.tbinfo.ch/de/publikationen/handbuch- tuberkulose.html; 2011.
43. Kucharz EJ, Korzeniewska-Koseła M, Kotulska A. Recommendations for prophylaxis and management of tuberculosis in patients treated with TNF-a antagonists. Reumatologia 2008; 46:51-54.
44. Centers for Disease Control and Prevention. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis Infection-United States, 2010. MMWR 2010; 59:1-25.
45. Canadian Tuberculosis Committee. Updated Recommendations on interferon gamma release assays for latent tuberculosis infection. CCDR 2010; 36:1-21.
46. Australian Rheumatology Association. Screening of latent tuberculosis infection (LTBI) prior to use of biological agents in Australia. Sydney: Therapeutics Committee of the Australian Rheumatology Association; 2010.
47. HPA Tuberculosis Programme Board. Health Protection Agency position statement on the use of Interferon Gamma Release Assay (IGRA) tests for tuberculosis (TB). London: Health Protection Agency 2008. 1-12.
48. Gonzalez-Martin J, Garcia-Garcia JM, Anibarro L, et al. Consensus document on the diagnosis, treatment and prevention of tuberculosis. Arch Bronconeu-mol 2010; 46:255-274.
49. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010; 36:1185-1206.
50. Al Jahdali HH, Baharoon S, Abba AA, et al. Saudi guidelines for testing and treatment of latent tuberculosis infection. Ann Saudi Med 2010; 30:38-49
51. European Centre for Disease Prevention and Control. Use of interferon-gamma release assays in support of TB diagnosis. Stockholm: ECDC; 2011. http://www.ecdc.europa.eu/en/publications/Publications/1103-GUI- IGRA.pdf.
52. Menzies D, Gardiner G, Farhat M, et al. Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results. Int J Tuberc Lung Dis 2008; 12:498-505. (Pubitemid 351703056)
53. Winthrop KL, Chiller T. Preventing and treating biologic-associated opportunistic infections. Nat Rev Rheumatol 2009; 5:405-410.